Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) EBITDA (2021 - 2025)

Historic EBITDA for Kezar Life Sciences (KZR) over the last 5 years, with Q2 2025 value amounting to -$14.6 million.

  • Kezar Life Sciences' EBITDA rose 3756.58% to -$14.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$75.7 million, marking a year-over-year increase of 2935.45%. This contributed to the annual value of -$90.6 million for FY2024, which is 1868.45% up from last year.
  • Latest data reveals that Kezar Life Sciences reported EBITDA of -$14.6 million as of Q2 2025, which was up 3756.58% from -$17.6 million recorded in Q1 2025.
  • In the past 5 years, Kezar Life Sciences' EBITDA registered a high of -$13.0 million during Q2 2021, and its lowest value of -$34.6 million during Q4 2023.
  • Moreover, its 5-year median value for EBITDA was -$20.0 million (2022), whereas its average is -$20.4 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 7265.15% in 2023, then soared by 3765.94% in 2024.
  • Quarter analysis of 5 years shows Kezar Life Sciences' EBITDA stood at -$14.1 million in 2021, then tumbled by 42.05% to -$20.0 million in 2022, then plummeted by 72.65% to -$34.6 million in 2023, then soared by 37.66% to -$21.6 million in 2024, then skyrocketed by 32.3% to -$14.6 million in 2025.
  • Its EBITDA stands at -$14.6 million for Q2 2025, versus -$17.6 million for Q1 2025 and -$21.6 million for Q4 2024.